Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. VS
VS logo

VS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Versus Systems Inc (VS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.970
1 Day change
7.18%
52 Week Range
2.830
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Versus Systems Inc (VS) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is weak, with revenue dropping to zero in the latest quarter, and there are no strong positive catalysts or trading signals to justify an investment at this time.

Technical Analysis

The technical indicators show a bearish trend with moving averages in a downward pattern (SMA_200 > SMA_20 > SMA_5). While the MACD is positive and expanding, the RSI is neutral, and the stock remains below key resistance levels. The stock has a 40% chance to decline by -1.29% in the next day and has limited upside potential in the short term.

Positive Catalysts

  • Renewed partnership with the Texas Rangers for the 2026 MLB season, which could enhance fan engagement through its Filter Fan Cam product.

Neutral/Negative Catalysts

  • The company reported a 100% YoY revenue drop in Q3 2025, with net income and EPS also significantly declining. Gross margin slightly decreased, and there are no significant insider or hedge fund trading trends to indicate confidence in the stock.

Financial Performance

In Q3 2025, revenue dropped to $0 (-100% YoY), net income fell to -$537,815 (-4.11% YoY), and EPS declined to -0.11 (-50% YoY). Gross margin decreased slightly to 99.25% (-0.75% YoY). Overall, the financial performance is extremely weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No direct analyst ratings or price target changes for Versus Systems Inc. The provided analyst note pertains to a different company and is not relevant to this stock.

Wall Street analysts forecast VS stock price to rise
Analyst Rating
0
Wall Street analysts forecast VS stock price to rise
Buy
Hold
Sell
0
Current: 0.905
sliders
Low
0
Averages
0
High
0
0
Current: 0.905
sliders
Low
0
Averages
0
High
0
UBS
Mauricio Serna
Buy
maintain
$60 -> $73
AI Analysis
2026-01-08
Reason
UBS
Mauricio Serna
Price Target
$60 -> $73
AI Analysis
2026-01-08
maintain
Buy
Reason
UBS analyst Mauricio Serna raised the firm's price target on Victoria's Secret to $73 from $60 and keeps a Buy rating on the shares. CY26 EPS upside for Softline stocks is expected to be driven by a stronger-than-expected U.S. consumer and an underappreciated "Health & Wellness 2.0" trend, with estimates at least 4% above consensus for 16 names, the analyst tells investors in a research note. Earnings momentum is projected to extend into CY27, with EPS forecasts averaging about 5% above consensus, the firm adds.

People Also Watch